PRA1 Activators

The class of PRA1 activators encompasses a diverse set of compounds that could potentially influence the function or regulation of PRA1 indirectly. This can be achieved through various mechanisms such as the disruption of Golgi function and vesicular transport by agents like Brefeldin A, Monensin, and Nocodazole. Similarly, inhibitors of protein kinases like Staurosporine, the PI3K inhibitor Wortmannin, and the mTOR inhibitor Rapamycin could potentially affect the pathways regulating PRA1.

Additionally, compounds that can inhibit protein synthesis like Cycloheximide, RNA synthesis like Actinomycin D, or CRM1-dependent nuclear export like Leptomycin B, could potentially influence the activity of PRA1. Furthermore, agents that can disrupt membrane organization like Nystatin and Filipin III, or the prenylation of Rab GTPases like Manumycin A, could potentially affect PRA1 activity.